WuXi AppTec Hits Limit Up on Blowout First-Half Results, Lifting Healthcare Services Sector

EarningsCorporate Action Impact 4
โดย 的化学业务营业收入同比增长53.28%·Read original
Summary · why it matters

On August 4, the healthcare services sector was active, with WuXi AppTec, Berry Genomics, Baihua Pharmaceutical, Asymchem, and Chuangxin Medical hitting their daily limit up, while Porton Pharma Solutions, Pharmaron, and others also rose. On the news front, WuXi AppTec released its 2026 semi-annual report on the evening of August 3. First-half revenue reached 28.897 billion yuan, up 38.93 percent year on year, and net profit attributable to shareholders of the listed company was 11.08 billion yuan, up 29.43 percent. Second-quarter revenue hit a record high of 16.462 billion yuan. The company also disclosed an interim dividend plan, proposing a cash dividend of 5.1 yuan per 10 shares, totaling 1.506 billion yuan. WuXi AppTec raised its full-year 2026 guidance across the board, lifting its expected total revenue from a range of 51.3 billion to 53 billion yuan to a range of 58.5 billion to 60.5 billion yuan, and raising its continuing operations revenue growth forecast from 18 to 22 percent to 35 to 39 percent. Fu Yifu, a special researcher at Suning Bank, said WuXi AppTec's better-than-expected semi-annual report injected a shot of confidence into the healthcare services sector and revived valuation sentiment. Jiang Han, a senior researcher at Pangu Think Tank, noted that the company's unique CRDMO business model continues to gain momentum, with more late-stage clinical and commercial projects, and warming investment and financing in innovative drugs driving a synchronized uptick in CXO demand. As of the midday close, WuXi AppTec shares were at 141.35 yuan, giving it an A-share market capitalization of 421.8 billion yuan.

Impact on stocks 7

Others▲ · 7 stocks

Theme Impact 1

Related news

Avantor Expands RIM Single-Use Bioprocessing Portfolio Across APAC

Avantor has expanded the availability of its RIM single-use bioprocessing portfolio across the Asia Pacific region, strengthening its presence in a key biopharma manufacturing market. The portfolio includes single-use consumables such as bioprocessing bags, assemblies, tubing and components, plus mixing and storage hardware, and is manufactured at Avantor's Changzhou, China facility, the company's first single-use production site in APAC. That 2,600-square-meter plant operates under ISO 9001:2015 certification and Good Manufacturing Practice standards, and RIM products are available exclusively to APAC customers. The move aligns with management's broader Revival strategy, and in the second quarter of 2026 the Bioscience & Medtech Products segment posted double-digit order growth and a book-to-bill ratio of 1.1x, with management expecting the segment to return to organic growth in the second half of 2026. Avantor currently has a market capitalization of $10.56 billion, and its shares have gained 38.4% year to date versus 3.4% growth for the industry and a 10.1% rise in the S&P 500.
AVTR ▲
Biotech & Genomic Medicine
Zacks Investment Research·17hRead more →
▲

Andelyn Begins Commercial Manufacturing of Ultragenyx's FDA-Approved FAYUVI Gene Therapy

Andelyn Biosciences announced it is now manufacturing FAYUVI, Ultragenyx Pharmaceutical Inc.'s FDA-approved gene therapy for Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, for commercial supply at its Columbus, Ohio facility. The move follows the U.S. Food and Drug Administration's approval of FAYUVI, making it the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator Platform process. Sanfilippo syndrome type A is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood; it is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years. Andelyn Chief Executive Officer Wade Macedone said the company is proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process, calling the milestone a reflection of the purpose behind Andelyn's founding. Andelyn, a full-service FDA-inspected cell and gene therapy commercial CDMO with more than 20 years of experience, has produced clinical and commercial material for more than 500 cGMP batches and 85 global clinical trials.
RARE ▲
Biotech & Genomic Medicine ▲
PR Newswire·18hRead more →
▲2

Charles River Laboratories Launches Rapid Cell Banking Platform With 40% Faster Production

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.
CRL
Biotech & Genomic Medicine ▲
Simply Wall St·21hRead more →
© 2026 MarketDXNews